We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

11 hedge funds and large institutions have $109K invested in Windtree Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

175% more funds holding

Funds holding: 4 → 11 (+7)

0.13% less ownership

Funds ownership: 0.2% → 0.07% (-0.13%)

72% less capital invested

Capital invested by funds: $390K → $109K (-$281K)

Holders
11
Holders Change
+7
Holders Change %
+175%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$75.7K
2
UBS Group
UBS Group
Switzerland
+$37.6K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$37.5K
4
XT
XTX Topco
Cayman Islands
+$12.3K
5
Two Sigma Investments
Two Sigma Investments
New York
+$9.17K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$375K
2
Morgan Stanley
Morgan Stanley
New York
-$8.87K
3
IA
IFP Advisors
Florida
-$2

WINT Hedge Fund Activity: Q4 2024 in Review

11 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q4 2024, worth a combined $109K — down 72% from $390K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new WINT positions and 2 closed out — a net gain of 7 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $75.7K. The largest seller was Armistice Capital, exiting entirely with an estimated $375K sold.

  • 11 institutional investors held Windtree Therapeutics (WINT) as of Q4 2024, up from 4 in Q3 2024.
  • Funds reported $109K of Windtree Therapeutics stock for Q4 2024, down 72% quarter-over-quarter.
  • 9 funds opened new Windtree Therapeutics positions in Q4 2024 and 2 closed out, a net change of +7 holders.
  • The largest Windtree Therapeutics buyer in Q4 2024 was Renaissance Technologies, an estimated $75.7K added.
  • The largest Windtree Therapeutics seller in Q4 2024 was Armistice Capital, an estimated $375K sold.

Based on aggregated 13F filings for Q4 2024.